The Zhitong Finance App learned that Viva Biotech (01873) rose more than 20% in the afternoon. As of press release, it rose 19.59% to HK$1.77, with a turnover of HK$32.024 million.

According to the news, recently, Viva Biotech and West Point Pharmaceuticals reached an AI-driven reverse targeting research and development cooperation. On Etovia Biotech's Mol2Mars platform, the two parties have built a closed loop of innovative target discovery and development of “AI computation+experimental verification” around research on the potential mechanism of action of drug molecules and target systems, providing a new scientific basis for analyzing the mechanism of action of drugs and expanding indications.

According to China Merchants Securities, as of the first half of 2026, CAD/AIDD had participated in 228 projects and 92 procurement customers; revenue from AI participation in enabling projects accounted for about 14.0% of CRO revenue, and about 15.0% of wet test revenue related to AI customers. The company upgraded and launched the MARS multi-modal integrated algorithm platform, built significant technical barriers in the field of peptides, cyclic peptides and complex macrocyclic compounds, and comprehensively upgraded the three underlying modules.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.